Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 509 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: No Disease Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Diindolylmethane in Preventing Cancer in Healthy Volunteers

NCT00784394
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
diindolylmethane, placebo, pharmacological study, laboratory biomarker analysis, quality-of-life assessment
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer

NCT00009945
View directory record Official record
Conditions
Breast Cancer
Interventions
clodronate, placebo
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
3,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
17
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

NCT02277704
View directory record Official record
Conditions
PTSD
Interventions
TNX-102 SL, Placebo
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Imperial, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers

NCT02090933
View directory record Official record
Conditions
No Evidence of Disease
Interventions
Celecoxib, Laboratory Biomarker Analysis, UV Light Therapy
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation

NCT01447355
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Skin Cancer
Interventions
cholecalciferol
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 6, 2026, 4:51 PM EDT
Completed No phase listed Observational

Early Diagnosis of Steroid-Responsive & No-Responsive Hearing Loss

NCT00013468
View directory record Official record
Conditions
Hearing Loss
Interventions
Tinnitus
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 6, 2026, 4:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Maestro Agreement and Precision Study II

NCT02376868
View directory record Official record
Conditions
Normal Healthy Subjects With No Known Ocular Diseases, Glaucomatous Eyes, Eyes With Retinal Diseases
Interventions
3D OCT-1 Maestro, iVue
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Not applicable Interventional

ENLIGHTEN: Exercise and NutritionaL Interventions for coGnitive and Cardiovascular HealTh ENhancement

NCT01573546
View directory record Official record
Conditions
Cognitive Impairment, no Dementia (CIND)
Interventions
Aerobic Exercise, DASH diet, Health education control
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
55 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of 9cUAB30 in Healthy Participants

NCT00896974
View directory record Official record
Conditions
No Evidence of Disease
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Retinoid 9cUAB30
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Sep 6, 2026, 4:51 PM EDT
Terminated Phase 2 Interventional Results available

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

NCT04871529
View directory record Official record
Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Interventions
Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride, Carboplatin
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
92
States / cities
Aurora, Colorado • Highlands Ranch, Colorado • Orlando, Florida + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Caregiver Empathy by Empowering Patients to Discuss Their Values

NCT05055141
View directory record Official record
Conditions
No Condition is the Focus of the Study
Interventions
Care to Share poster
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 6, 2026, 4:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants

NCT00899457
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Lung Cancer
Interventions
proteomic profiling, biologic sample preservation procedure, laboratory biomarker analysis, bronchoscopy
Genetic · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Sep 6, 2026, 4:51 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Optimizing Lymphatic Pumping for Influenza Vaccine Responses in Vulnerable Populations

NCT07786467
View directory record Official record
Conditions
No Disease or Condition is Being Directly Studied, The Focus of the Study in Healthy Volunteers
Interventions
Osteopathic manipulation, Sham
Other
Lead sponsor
Lake Erie College of Osteopathic Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Active, not recruiting Phase 3 Interventional

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Whittier, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Terminated Not applicable Interventional

Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)

NCT04397692
View directory record Official record
Conditions
Corona Virus Infection, COVID-19, SARS-CoV 2, Nitric Oxide, Respiratory Disease, Pneumonia, Viral, Inhaled Nitric Oxide
Interventions
Nitric Oxide delivered via LungFit™ system
Device
Lead sponsor
Beyond Air Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Sep 6, 2026, 4:51 PM EDT
Active, not recruiting Not applicable Interventional

Sling vs No Sling After Reverse Total Shoulder Arthroplasty

NCT06092996
View directory record Official record
Conditions
Shoulder Disease, Rotator Cuff Tear Arthropathy, Shoulder Osteoarthritis
Interventions
Time of Sling Use
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 1 Interventional

Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available

NCT00768391
View directory record Official record
Conditions
Solid Tumors
Interventions
IMC-3G3
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Indianapolis, Indiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers

NCT01950403
View directory record Official record
Conditions
Colorectal Cancer, Healthy, no Evidence of Disease
Interventions
linaclotide acetate, placebo, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 1 Interventional

A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes

NCT00001005
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 6, 2026, 4:51 PM EDT
Recruiting Phase 2 Interventional

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

NCT05239546
View directory record Official record
Conditions
Colon Cancer, dMMR Colorectal Cancer
Interventions
Dostarlimab
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Recruiting Not applicable Interventional

Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection

NCT06004739
View directory record Official record
Conditions
Infectious Disease
Interventions
Start Antibiotics / Continue Antibiotics for treatment of bacteriuria, No Antibiotics for treatment of bacteriuria
Drug · Other
Lead sponsor
Mount Sinai Hospital, Canada
Other
Eligibility
60 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lycopene in Healthy Male Participants

NCT00450957
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Prostate Cancer
Interventions
lycopene, pharmacological study
Dietary Supplement · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 6, 2026, 4:51 PM EDT
Completed No phase listed Observational

CanGaroo® Registry Study

NCT04846127
View directory record Official record
Conditions
Arrhythmias, Cardiac
Interventions
CanGaroo Envelope
Device
Lead sponsor
Elutia Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
23
States / cities
Little Rock, Arkansas • Daytona Beach, Florida • Delray Beach, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

NCT02780401
View directory record Official record
Conditions
HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim
Other · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Seattle, Washington • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 6, 2026, 4:51 PM EDT